MCA Stability Tool

Find stability recommendations for tablets and capsules.

Product Search

Stability Notes

Protect from moisture and light.

Provenance

This compatibility recommendation is derived from Dapsone 50mg tablets (Accord Healthcare Ltd).

Stability Notes

Protect from light. Store in airtight containers.

Provenance

This compatibility recommendation is derived from Daraprim 25mg tablets (GlaxoSmithKline UK Ltd).

Stability Notes

Protect from light.

Provenance

This compatibility recommendation is derived from Emselex 7.5mg modified-release tablets (Aspire Pharma Ltd).

Stability Notes

Protect from light.

Provenance

This compatibility recommendation is derived from Emselex 7.5mg modified-release tablets (Aspire Pharma Ltd).

Stability Notes

Protect from light.

Provenance

This compatibility recommendation is derived from Emselex 7.5mg modified-release tablets (Aspire Pharma Ltd).

Stability Notes

Protect from light.

Provenance

This compatibility recommendation is derived from Emselex 7.5mg modified-release tablets (Aspire Pharma Ltd).

Stability Notes

Does not require any special storage conditions.

Provenance

This compatibility recommendation is derived from Prezista 400mg tablets (Janssen-Cilag Ltd).

Stability Notes

Does not require any special storage conditions.

Provenance

This compatibility recommendation is derived from Prezista 400mg tablets (Janssen-Cilag Ltd).

Stability Notes

Does not require any special storage conditions.

Provenance

This compatibility recommendation is derived from Prezista 600mg tablets (Janssen-Cilag Ltd).

Stability Notes

Does not require any special storage conditions.

Provenance

This compatibility recommendation is derived from Prezista 600mg tablets (Janssen-Cilag Ltd).

Stability Notes

Does not require any special storage conditions.

Provenance

This compatibility recommendation is derived from Prezista 600mg tablets (Janssen-Cilag Ltd).

Print this list

Medicines under this category are suitable for use inside MCAs, although this is likely to be an off-label use.
Medicines under this category can theoretically be used inside an MCA; however, mitigations may need to be considered.
Medicines under this category are not suitable for use inside MCAs.
We do not have stability information for these medicines and therefore cannot make a recommendation on suitability in an MCA.